Fed Up Of Poorly Run Academic Spin-Outs? Try This Instead
Three big pharma and three major UK universities are working together to "find, fund and run academic drug discovery projects at a pharma quality level." The collaboration has had a productive first year with four programs underway, two more about to be finalized, and "a good flow" in the pipeline, according to CEO Dr Richard Butt.
You may also be interested in...
Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.